[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-melanoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,84,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100588387","phase-1-a-study-to-investigate-the-safety-and-efficacy-of-iov-3001-in-adults-with-advanced-melanoma-who-will-receive-lifileucel-100588387",false,"NCT06940739","A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","A Phase 1\u002F2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel","Inclusion Criteria:\n\n1. Participant must be ≥ 18 years of age at the time of signing the informed consent.\n2. Participant has unresectable or metastatic melanoma.\n3. Participant has melanoma not of uveal\u002Focular origin and experienced documented radiographic disease progression during systemic therapy with a PD-1\u002FPD-L1 blocking antibody or within 12 weeks after the last dose of the PD-1\u002FPD-L1 blocking antibody. If the tumor is BRAF V600 mutation positive, the participant also received or refused a BRAF inhibitor with or without a MEK inhibitor.\n\n   OR Phase 1, Part 1 only: For participants with uveal melanoma, tebentafusp must have been received if available as standard of care (human leukocyte antigen \\[HLA\\]-A\\*02:01 positive participant and approved by local authorities for uveal melanoma) or refused.\n4. Participant has an ECOG performance status of 0 or 1 and, in the investigator's opinion, an estimated life expectancy of \\> 6 months.\n5. Phase 1, Part 2 only: Following tumor resection for lifileucel generation, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1.\n6. Participant has recovered from all prior anticancer treatment-related AEs\n\nExclusion Criteria:\n\n1. Participant has symptomatic untreated brain metastases.\n2. Participant is at an increased risk for systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.\n3. Participant has active uveitis that requires active treatment.\n4. Participant has any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease \\[SCID\\] or AIDS).\n5. Participant has a history of hypersensitivity to any component of the study intervention.\n6. Participant had another primary malignancy within the previous 3 years.\n7. Participants who require systemic steroid therapy 10 mg\u002Fday prednisone or another steroid equivalent dose.\n8. Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.","ALL","18 Years","70 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","A Phase 1\u002F2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.",[28,29,30],"Unresectable Melanoma","Metastatic Melanoma","Ocular Melanoma",[32,33,28,29,34,35,36,37,38,39,40,41,42,43],"Tumor Infiltrating Lymphocytes","TIL","Cell Therapy","Autologous Adoptive Cell Therapy","Cellular Immuno-therapy","IL-2","Autologous Adoptive Cell Transfer","Melanoma","Lifileucel","Stage IV Melanoma","Malignant Melanoma","Uveal Melanoma","RECRUITING","2026-06-11",{"date":47,"type":48},"2026-06-15","ACTUAL",{"date":50,"type":48},"2025-03-11",{"date":52,"type":21},"2032-07",{"name":54,"class":55},"Iovance Biotherapeutics, Inc.","INDUSTRY",5,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100516681","phase-3-a-phase-3-randomized-masked-controlled-trial-to-evaluate-efficacy-and-safety-of-belzupacap-sarotalocan-au-011-treatment-compared-to-sham-control-in-subjects-with-primary-indeterminate-lesions-or-small-choroidal-melanoma-100516681","NCT06007690","A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","CoMpass","Inclusion Criteria:\n\n* Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL\u002FCM)\n* Have no evidence of metastatic disease confirmed by imaging\n* Be treatment naive for IL\u002FCM (subjects who received PDT may be eligible)\n\nExclusion Criteria:\n\n* Have known contraindications or sensitivities to the study drug or laser\n* Active ocular infection or disease",{"count":65,"type":21},100,[67],"PHASE3","The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).",[70,71,43,30],"Choroidal Melanoma","Indeterminate Lesions",[43,73,30,70],"Eye Cancer","2026-02-26",{"date":76,"type":48},"2026-03-02",{"date":78,"type":48},"2023-12-06",{"date":80,"type":21},"2028-08-15",{"name":82,"class":55},"Aura Biosciences",71,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":103},"100625369","choroidal-melanoma-patient-reported-outcome-study-cm-pro-in-a-subset-of-au-011-301-compass-subjects-100625369","NCT07421739","Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects","Inclusion Criteria:\n\n* Have enrolled in the Aura-sponsored clinical trial AU-011-301.\n* Access to a connected device (i.e., smartphone, laptop, or tablet)\n\nExclusion Criteria:\n\n* None",{"count":91,"type":21},15,"OBSERVATIONAL","To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.",[70,71,43,30],[43,73,30,70],"2026-02-17",{"date":98,"type":48},"2026-02-19",{"date":100,"type":48},"2025-11-12",{"date":80,"type":21},{"name":82,"class":55},1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":103},"100590655","resistance-exercise-in-patients-with-ocular-melanoma-100590655","NCT06970236","Resistance Exercise in Patients With Ocular Melanoma","Impact of an In-hospital Exercise Program on the Health of Patients With Ocular Melanoma Undergoing Plaque Brachytherapy: A Randomized Controlled Trial","IHOPE","Inclusion Criteria:\n\n* Adults with Choroidal Melanoma diagnose and treated with plaque brachytherapy undergoing in \"Hospital Universitari i Politècnic La Fe\" (Valencia).\n\nExclusion Criteria:\n\n* Present a health status that forbids high intensity resistance training.\n* Have any unsteady cardiac illness.\n* Have serious metabolic disorder.\n* Have any important orthopaedic disorder impeding exercise.",{"count":113,"type":21},40,[115],"NA","Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training during hospitalization on health-related blood biomarkers in CM patients. Our secondary aim will be to assess changes in physical function tests, quality of life and anxiety and depression. Candidates for this study will be patients undergoing CM treatment at the \"Hospital Universitari i Politècnic La Fe\" of Valencia.",[30],"2025-05-21",{"date":120,"type":48},"2025-05-28",{"date":122,"type":48},"2025-02-01",{"date":124,"type":21},"2026-12",{"name":126,"class":127},"University of Valencia","OTHER"]